‘Please Don’t:’ Analysts Scorn Unilever’s Takeover Ambitions

Bloomberg2022-01-17

“This is a very bad deal,” writes analyst at BernsteinUnilever shares plunge 7%, biggest drop in almost two yearsA production line inside the Unilever NV factory in Rotterdam, Netherlands.Photographer...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

vlcs
2022-01-18
vlcs
Ok
Jo Tan
2022-01-18
Jo Tan
good article!
Tgbdisciple
2022-01-18
Tgbdisciple
Nice
estherytwu
2022-01-18
estherytwu
Ok
Ghossstsam
2022-01-18
Ghossstsam
Wow
7united
2022-01-18
7united
Hi

Leave a comment

141

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2204377538?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-01-17 21:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2204377538","market":"us","top_or_hot":-1,"title":"‘Please Don’t:’ Analysts Scorn Unilever’s Takeover Ambitions","media":"Bloomberg","content":"<div>\n<p>“This is a very bad deal,” writes analyst at BernsteinUnilever shares plunge 7%, biggest drop in almost two yearsA production line inside the Unilever NV factory in Rotterdam, Netherlands.Photographer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-01-17/-please-don-t-analysts-scorn-unilever-s-takeover-ambitions?srnd=premium\">Source Link</a>\n\n</div>\n","source":"lsy1584095487587","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>‘Please Don’t:’ Analysts Scorn Unilever’s Takeover Ambitions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n‘Please Don’t:’ Analysts Scorn Unilever’s Takeover Ambitions\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 21:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2022-01-17/-please-don-t-analysts-scorn-unilever-s-takeover-ambitions?srnd=premium><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>“This is a very bad deal,” writes analyst at BernsteinUnilever shares plunge 7%, biggest drop in almost two yearsA production line inside the Unilever NV factory in Rotterdam, Netherlands.Photographer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-01-17/-please-don-t-analysts-scorn-unilever-s-takeover-ambitions?srnd=premium\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GSK","symbol_name":"葛兰素史克","start_time":0,"source_url":"https://www.bloomberg.com/news/articles/2022-01-17/-please-don-t-analysts-scorn-unilever-s-takeover-ambitions?srnd=premium","article_id":"2204377538","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2204377538","pubTimestamp":1642426106,"sourceInfo":{"source_id":"lsy1584095487587","name":"Bloomberg"},"weMediaInfo":null,"summary":"“This is a very bad deal,” writes analyst at BernsteinUnilever shares plunge 7%, biggest drop in alm","collect":0,"end_time":0,"defaultTopTitle":"bloomberg.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"GSK":"葛兰素史克","BK4183":"个人用品"},"translate_title":"分析师鄙视联合利华的收购野心","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK":0.6},"content_text":"“This is a very bad deal,” writes analyst at BernsteinUnilever shares plunge 7%, biggest drop in almost two yearsA production line inside the Unilever NV factory in Rotterdam, Netherlands.Photographer: Jasper Juinen/BloombergAnalysts are denouncing Unilever Plc’s 50 billion pound ($68 billion) offer for GlaxoSmithKline Plc’s consumer health business in unusually strong words.In a barrage of Monday morning notes, analysts criticized Unilever for pursuing the deal, saying it doesn’t make sense and would come at an eye-watering valuation. Consumer health isn’t a high-growth industry and Unilever has a bad track record for big deals, said Bruno Monteyne at Bernstein.“We can’t imagine many things that would unnerve us more about Unilever than acquiring GSK consumer health,” wrote James Edwardes Jones at RBC Capital Markets in a note titled “Please Don’t.”Unilever has no overlap with two-thirds of Glaxo’s consumer health business and little experience in regulatory issues for medical and clinical products, said Edwardes Jones at RBC. “We had been considering whether the time was ripe to abandon our underperform rating,” he added. “We’re not any more.”Investors responded by dumping Unilever shares, sending the stock price down as much 7.3%, the biggest drop in almost two years. Glaxo shares gained 3.7% in London.Glaxo in a statement Saturday said that it had received three unsolicited offers from Unilever for its consumer healthcare division, the final one on Dec. 20 for 41.7 billion pounds in cash and 8.3 billion pounds in Unilever shares. Glaxo said it rejected the proposals because they undervalue the business.Unilever is still interested and could return with a fresh bid, though no final decision has been made, people familiar with the bid told Bloomberg. Glaxo’s board still prefers the planned spin-off of a business that includes brands such as Sensodyne toothpaste and Advil painkillers.Analysts said Unilever would have to significantly increase its bid to tempt Glaxo away from the spin-off plan. If a deal emerges at 55 billion pounds, “we think Unilever is paying at least 10 billion pounds more than they should pay for the growth they get,” said Bernstein’s Monteyne. “This is a very bad deal.”The positive is that Unilever would become a world leader in consumer health and gain iconic brands that it could expand in emerging markets, wrote Warren Ackerman at Barclays Plc.But it would come at a high price. Barclays estimated that based on the latest offer and consensus forecasts for Glaxo’s consumer business, the valuation multiple is 20 times Ebitda. Very few deals at that high of a multiple have created value, Ackerman said.“With management credibility already an issue, this deal will be hard to stomach even given the many positives that we also see,” he added.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9004058708,"gmtCreate":1642463385467,"gmtModify":1676533712115,"author":{"id":"4093078314770720","authorId":"4093078314770720","name":"vlcs","avatar":"https://static.itradeup.com/news/aa49779e3b2078429bce79d047d188e3","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004058708","repostId":2204377538,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004051488,"gmtCreate":1642463140987,"gmtModify":1676533712084,"author":{"id":"4103923793959030","authorId":"4103923793959030","name":"Jo Tan","avatar":"https://community-static.tradeup.com/news/25f349ba1560882a8ae004ed0b7060bf","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"good article!","listText":"good article!","text":"good article!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004051488","repostId":2204377538,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004069117,"gmtCreate":1642460037126,"gmtModify":1676533711518,"author":{"id":"3575247585577854","authorId":"3575247585577854","name":"Tgbdisciple","avatar":"https://static.tigerbbs.com/7c099c9cab7661dd2fa5c44752e05414","vip":1,"crmLevel":3,"crmLevelSwitch":1},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004069117","repostId":2204377538,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004082573,"gmtCreate":1642459500188,"gmtModify":1676533711391,"author":{"id":"3580294349597017","authorId":"3580294349597017","name":"estherytwu","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004082573","repostId":2204377538,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004088127,"gmtCreate":1642459258975,"gmtModify":1676533711323,"author":{"id":"3575242933917282","authorId":"3575242933917282","name":"Ghossstsam","avatar":"https://static.tigerbbs.com/4f40137f908781b15d3832845cc3f732","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004088127","repostId":2204377538,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9004033963,"gmtCreate":1642439889391,"gmtModify":1676533710740,"author":{"id":"4101867685462840","authorId":"4101867685462840","name":"7united","avatar":"https://static.tigerbbs.com/c58862424d0a0bd2f497e595d175522e","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004033963","repostId":2204377538,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":141,"commentSize":14,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2204377538"}